On February 19, 2020, the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff had determined to delist the Company’s common shares from Nasdaq unless the Company requests a hearing before the Panel by February 26, 2020, which the Company will do. This request will ordinarily stay any further action by the Staff and the Company’s securities are expected to continue to be eligible to trade on Nasdaq at least pending the ultimate conclusion of the hearing process.

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Neovasc, Inc. (NASDAQ:NVCN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 4:30 PM Eastern ...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 26, 2020) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today 1) an offering ("Offering") of convertible notes ("2020 Notes") and warrants ("2020 Warrants") to Strul Medical Group for gross proceeds of up to US$5.0 Million; 2) all ...

To evidence compliance with the MVLS requirement, the Company must evidence an MVLS of at least $35 million based upon the consolidated closing bid price of Neovasc’s common stock for a minimum of 10 consecutive business days. The Company intends to pursue opportunities to raise additional capital with the goal to timely evidence compliance with the MVLS requirement.

VANCOUVER and MINNEAPOLIS, Feb. 12, 2020 -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally.

In the study published in EuroIntervention, “Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina,” in patients with obstructive coronary artery disease suffering from chronic refractory angina, treatment with coronary sinus Reducer implantation was associated with objective improvement in exercise capacity and oxygen kinetics tested by cardiopulmonary exercise testing as well as improvement in angina symptoms and quality of life. Patients with chronic refractory angina were treated with Reducer implantation at 2 medical centers: the Antwerp Cardiovascular Center in Belgium and the Tel Aviv Medical Center in Israel.

VANCOUVER, March 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and year ended December 31, 2019 after the market close on March 30, 2020. Neovasc CEO Fred Colen and CFO Chris Clark will host a conference call to review the company’s results at 4:30 PM Eastern Time. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

The MVLS test is based on the closing bid price each day. If the Company maintains an MVLS of at least $35 million for ten consecutive trading days, it will satisfy the MVLS requirement before the Nasdaq grace period ends on February 17, 2020. The Nasdaq has discretion to require satisfaction of the $35 million MVLS requirement for a period in excess of ten consecutive trading days.

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 12, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today achievement of design freeze for its fully retrievable transfemoral trans-septal Tiara™ ("TF/TS Tiara") system, including a modified, lower profile valve and a steerable ...

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NASDAQ: FTSV) * Ra Pharmaceuticals Inc (NASDAQ: RARX) * Quidel Corporation (NASDAQ: QDEL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) * Aikido Pharma Inc (NASDAQ: AIKI) * BIOLASE Inc (NASDAQ: BIOL) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Gritstone Oncology Inc (NASDAQ: GRTS) * Neovasc Inc (NASDAQ: NVCN)(moved in reaction to its fourth quarter results) * Opko Health Inc. (NASDAQ: OPK) * Phio Pharmaceuticals Corp (NASDAQ: PHIO)(announced $4 million registered offering) * Second Sight Medical Products Inc (NASDAQ: EYES)Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning JudgmentStocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX) said it has enrolled and dosed the first patient into a randomized clinical trial investigating the safety and efficacy of IFX-1, its monoclonal anti-C5a antibody in patients with severe COVID-19-induced pneumonia. The trial is being initiated in the Netherlands.The decision to initiate human testing follows initial positive human data from two patients suffering from COVID-19-induced pneumonia, who were treated with BDB-001, an anti-C5a antibody produced from BDB from the IFX-1 cell line, in China.The company said it plans to initiate additional centers in Germany and potentially other European countries.In pre-market trading Wednesday, InflaRx shares were jumping 114.66% to $8.20.Emergent Biosolutions To Provide CDMO Services For Novavax's Flu Vaccine Candidate Novavax, Inc. (NASDAQ: NVAX) and Emergent Biosolutions Inc (NYSE: EBS) announced an agreement, whereby the latter would provide molecule-to-market contract development and manufacturing to produce the former's recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.Novavax recently announced positive results for the late-stage trial that evaluated the vaccine candidate.Novavax shares were adding 3.09% to $14 in pre-market trading.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Mesoblast's Regulatory Filing For Graft Vs. Host Disease Drug Accepted For Priority Review Mesoblast limited (NASDAQ: MESO) said the FDA has accepted for priority review its BLA for Ryoncil, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease. The PDUFA date has been set for Sept. 30, the company noted.View more earnings on IFRXThe stock was advancing 8.45% to $4.75 in pre-market trading.Eisai To Co-develop And Commercialize Seikagaku's Osteoarthritis Drug In China Eisai Co., Ltd (OTC: ESALY) announced an agreement with Seikagaku for co-developing and marketing of SI-613 in China. SI-613 is a therapeutic agent for osteoarthritis discovered by Seikagaku.Chembio Launches Serological COVID-19 Detection Test In U.S. Chembio Diagnostics Inc (NASDAQ: CEMI) said it has launched in the U.S. the rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies."These results can be obtained within 15 minutes from a simple finger stick utilizing Chembio's MicroReader 1 and MicroReader 2 analyzers which are produced by Chembio Germany," the company said.The stock was jumping 23.05% to $6.30 in after-hours trading.Becton Dickinson Releases COVID-19 Test Developed By BioMedomics Medtech company Becton Dickinson and Co (NYSE: BDX) and privately held diagnostics company BioMedomics announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes.The new test developed and manufactured by BioMedomics will be available through BD and distributed exclusively by Henry Schein, Inc. (NASDAQ: HSIC) to health care providers throughout the U.S.BD shares were adding 0.97% to $232 in pre-market trading.Ultragenyx Out-licenses Gene Therapy Platforms And In-licenses Gene Therapy Vectors Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced a strategic partnership and non-exclusive license and technology access agreement with DAIICHI SANKYO/S ADR (OTC: DSNKY) for its AAV-based gene therapy manufacturing technologies, namely its HeLa PCL and HEK293 transient transfection manufacturing technology platforms.The agreement provides for Daiichi Sankyo making an upfront payment of $125 million and an equity investment amounting to $75 million at about $60 per share in Ultragenyx. Daiichi Sankyo will pay an additional $25 million upon completion of the technology transfer of the HeLa PCL and HEK293 platforms as well as single-digit royalties on net sales of products manufactured in either system.Separately, Ultragenyx and Regenxbio Inc (NASDAQ: RGNX) announced a new exclusive, worldwide license agreement, extending the companies' existing gene therapy partnership. Under the agreement, REGENXBIO has granted Ultragenyx an exclusive, worldwide license, with rights to sublicense, to its NAV AAV8 and AAV9 vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder. Regenxbio will be compensated with an upfront payment of $7 million, ongoing fees, milestone payments, and royalties on net sales of products incorporating the licensed intellectual property.On The Radar Earnings Ascendis Pharma A/S (NASDAQ: ASND) (after the market close)See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Professor Mitts will examine trading history related to the unusual volume and downward pressure on the price of the common shares of the Company after positive news releases, and the unusual volume and downward pressure on the price of the common shares of the Company after the Company announced an update on its compliance with the Nasdaq’s minimum value of listed securities rule. The findings of the commissioned report may be provided to appropriate authorities, including the Nasdaq.

VANCOUVER and MINNEAPOLIS, March 30, 2020 -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally.

The Company is increasingly bullish on Reducer and remains focused on capitalizing on the improving market dynamics for the device. Management believes the landscape for the treatment of refractory angina and ischemia is changing favorably. The increasing rate of diagnosis of microvascular disease provides support for the treatment of refractory angina with the Reducer in appropriate patients.

Promotes John Panton to Chief Quality Officer Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 7, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the first quarter ended March 31, 2020. First Quarter HighlightsFDA formally accepted Reducer PMA applicationRenewal of NUB ...

VANCOUVER and MINNEAPOLIS, MN, April 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2020 after the market close on May 7, 2020. Neovasc Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the company’s results at 4:30 PM Eastern Time. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.

Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.

After a marked slowdown that began in March, Reducer implant rates in Germany, where the company has a direct sales team and NUB Status 1 designation for reimbursement, are once again approaching pre-COVID-19 levels. As previously discussed, the company is aware of the backlog of potential Reducer patients related to COVID-19 and the reduction in elective procedures in select European markets and we look forward to continued acceleration. The National Institute for Health and Care Excellence (NICE) Interventional Procedures Programme in the U.K. has invited Neovasc to participate in guidance development for Reducer treatment of refractory angina.

Less invasive approach provides hope for the millions of patients that suffer from leaky mitral valves Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 27, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Company has filed for CE Mark for its Tiara TA Transapical ...

A replay of the webcast will be accessible through the Neovasc investor relations website approximately one hour following the completion of the event. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.